0
Signin
countryflagUS

18889881171

AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%

Vyne Therapeutics Inc

Healthcare US VYNE

2.3USD
-0.1(4.17%)

Last update at 2024-04-18T20:00:00Z

Day Range

2.252.39
LowHigh

52 Week Range

2.188.73
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -33.93200M -73.77700M -255.82600M -73.70300M -51.44500M
Minority interest - - - - -
Net income -33.94500M -73.32900M -255.56800M -70.46400M -51.44500M
Selling general administrative 16.39M 54.48M 89.54M 22.48M 12.19M
Selling and marketing expenses - - - - -
Gross profit 0.48M 11.41M 19.60M - 10.64M
Reconciled depreciation 0.07M 0.11M 0.34M 0.70M 0.02M
Ebit -34.29500M -68.03200M -113.47500M -76.94200M -54.55700M
Ebitda -33.93200M -68.16700M -112.02400M -76.24200M -54.53500M
Depreciation and amortization 0.36M -0.13500M 1.45M 0.70M 0.02M
Non operating income net other - - - - -
Operating income -34.29500M -68.03200M -113.47500M -76.24200M -54.53500M
Other operating expenses 34.77M 82.79M 134.47M 76.24M 65.17M
Interest expense 10.81M 5.61M 4.39M 2.54M 3.09M
Tax provision 0.01M -0.44800M -0.25800M - -
Interest income - - - - 3.09M
Net interest income 0.00000M -5.61000M -4.39000M 2.54M 3.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.01M -0.44800M -0.25800M -3.23900M 3.09M
Total revenue 0.48M 14.76M 20.99M 0.00000M 10.64M
Total operating expenses 34.77M 79.44M 133.08M 76.24M 65.17M
Cost of revenue - 3.35M 1.39M - -
Total other income expense net 0.36M -5.74500M -142.35100M 2.54M 3.09M
Discontinued operations 10.73M -29.12100M -29.12100M -29.12100M -
Net income from continuing ops -33.94500M -73.32900M -255.56800M -73.70300M -51.44500M
Net income applicable to common shares -23.21000M -73.32900M -255.56800M -95.17800M -74.16300M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 40.76M 67.05M 93.74M 79.17M 139.93M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 7.19M 0.34M 5.45M 1.38M 3.25M
Total liab 9.56M 18.41M 56.25M 10.66M 9.55M
Total stockholder equity 31.20M 48.64M 37.49M 68.51M 130.38M
Deferred long term liab - - - - -
Other current liab 6.96M 11.55M 0.10M 0.48M 6.25M
Common stock 1.47M 0.00500M 0.00400M 0.00300M 0.00300M
Capital stock 0.00000M 0.00500M 0.00400M 0.00300M 0.00300M
Retained earnings -662.73500M -639.52500M -566.19600M -184.33900M -110.63600M
Other liab - - 0.77M 0.88M 1.08M
Good will - - 4.54M - -
Other assets 2.48M 3.51M 4.90M 0.74M 0.18M
Cash 30.91M 42.25M 57.56M 30.78M 49.51M
Cash and equivalents - - - - -
Total current liabilities 9.35M 18.41M 21.45M 10.66M 9.54M
Current deferred revenue - - 15.81M 5.71M -
Net debt -31.25700M -41.90100M -22.77900M -30.07700M -49.51000M
Short term debt - 0.35M 0.76M 0.70M -
Short long term debt - - - - -
Short long term debt total -0.34900M 0.35M 34.78M 0.70M -
Other stockholder equity 692.26M 688.16M 603.68M 252.82M 101.18M
Property plant equipment - 0.35M 2.14M 4.58M 2.23M
Total current assets 38.27M 63.19M 87.26M 78.33M 139.50M
Long term investments - - - - 0.00000M
Net tangible assets 31.20M 48.64M 37.49M 17.57M 92.18M
Short term investments - 0.00000M 1.03M 46.17M 86.74M
Net receivables 5.17M 7.58M 15.82M 0.14M 1.07M
Long term debt - - 33.17M - -
Inventory 0.10M 7.29M 7.40M 1.36M -
Accounts payable 2.39M 6.51M 4.78M 3.77M 3.29M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - 0.02M -0.09600M
Additional paid in capital - - - - -
Common stock total equity - - 0.00400M 0.00300M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.20M 3.51M 4.34M 0.07M 0.28M
Deferred long term asset charges - - - - -
Non current assets total 2.48M 3.86M 6.48M 0.84M 0.43M
Capital lease obligations 0.00000M 0.35M 1.61M 0.70M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 15.67M 1.03M 89.11M 41.37M -33.87600M
Change to liabilities -8.68100M -2.67500M -12.97500M 18.05M 0.24M
Total cashflows from investing activities 15.67M 1.03M 89.11M 41.87M -11.75500M
Net borrowings - -36.43200M -36.43200M 33.90M 33.90M
Total cash from financing activities 1.65M 39.78M 61.81M 4.99M 125.91M
Change to operating activities -0.34900M -0.37100M -4.17000M -0.38900M -0.28800M
Net income -23.21000M -73.32900M -255.56800M -73.70300M -51.44500M
Change in cash -11.88000M -15.56300M 13.83M -18.73300M 39.30M
Begin period cash flow 42.85M 58.42M 44.58M 49.51M 10.21M
End period cash flow 30.98M 42.85M 58.42M 30.78M 49.51M
Total cash from operating activities -29.20000M -56.36700M -137.08200M -65.10100M -52.73300M
Issuance of capital stock 1.68M 75.98M 61.64M 4.53M 125.42M
Depreciation 0.07M 0.11M 0.34M 0.70M 0.02M
Other cashflows from investing activities 15.67M 15.67M 15.67M 15.67M -
Dividends paid - - - - -
Change to inventory 0.10M 0.11M -6.04800M -1.35600M 2.76M
Change to account receivables 11.21M 7.71M -17.13800M 0.37M 0.79M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.18M 0.23M 0.17M 0.47M 0.50M
Change to netincome -8.33900M 12.08M 158.48M 4.75M 5.54M
Capital expenditures 0.00000M 0.00000M 0.11M 0.01M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.28M 4.78M -40.33100M 1.89M -4.17400M
Stock based compensation 4.30M 8.08M 18.10M 6.70M 3.64M
Other non cash items -12.63600M 2.47M 84.07M -0.69100M -0.77400M
Free cash flow -29.20000M -56.36700M -137.19500M -65.11200M -52.87300M

Fundamentals

  • Previous Close 2.40
  • Market Cap35.17M
  • Volume11091
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-30.51100M
  • Revenue TTM0.35M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 0.48M
  • Diluted EPS TTM-9.06

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VYNE
Vyne Therapeutics Inc		 -0.1 4.17% 2.30 - - 104.09 3.15 10.04 0.22
NVO
Novo Nordisk A/S		 -1.78 1.43% 122.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.344 1.08% 122.81 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.38 0.10% 393.48 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 -1.042 1.18% 86.92 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Vyne Therapeutics Inc

520 U.S. Highway 22, Bridgewater, NJ, United States, 08807

Key Executives

Name Title Year Born
Mr. David T. Domzalski CEO, Pres & Director 1967
Dr. Iain A. Stuart Ph.D. Chief Scientific Officer 1973
Ms. Mutya Harsch J.D. Gen. Counsel, Chief Legal Officer & Company Sec. 1975
Mr. Tyler Zeronda CFO, Principal Accounting Officer & Treasurer 1986
Mr. David Schuz Sr. VP of Intellectual Property 1954
Dr. Russell Elliott D.Phil. Sr. VP of Pharmaceutical Devel. 1966
Dr. Darrell S. Rigel M.S., M.D., MS Consultant 1950

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).